## Convergence of risk prediction models in follicular lymphoma

Anjali Silva,[1] Sleiman Bassim,[1] Clémentine Sarkozy,[2] Anja Mottok,[3] Tracy Lackraj,[1] Vindi Jurinovic,[4,5] Marianne Brodtkorb,[6] Ole Christian Lingjaerde,[6] Laurie H. Sehn,[2] Randy D. Gascoyne,[2] Oliver Weigert,[4] Christian Steidl[2] and Robert Kridel[1]

[1]Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada; [2]Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada; [3]Institute of Human Genetics, Ulm University and Ulm University Medical Center, Germany; [4]Department of Medicine III, University Hospital, Ludwig Maximilians University Munich, Germany; [5]Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig Maximilians University Munich, Germany and [6]Centre for Cancer Biomedicine, Oslo University Hospital, Norway

Correspondence: ROBERT KRIDEL. robert.kridel@uhn.ca

Supplemental Figure 1. Overall survival (OS) by mGEP Score, clusters and both mGEP Score and m7-FLIPI. (A) OS by mGEP Score in our cohort. Five-year OS was 72% vs. 87% in patients with high and low mGEP Score, respectively. (B) OS by mGEP Score and m7-FLIPI in our cohort. Five-year OS was 35% in patients with high mGEP Score and high risk m7-FLIPI. (C) OS by cluster in our cohort. Five-year OS was 72% vs. 81% in patients with Cluster 2 and Cluster 1, respectively.

Supplemental Table 1: Association of individual FLIPI factors with clusters.

	N (%)			
	Evaluable	Cluster 1	Cluster 2	*P*
Age ≤ 60	137	32 (43%)	34 (55%)	0.21
Age > 60		43 (57%)	28 (45%)	
Age continuous	137	75 (100%)	62 (100%)	0.03
Hemoglobin ≥ 120g/l	130	59 (83%)	45 (76%)	0.45
Hemoglobin < 120g/l		12 (17%)	14 (24%)	
LDH normal	130	59 (83%)	45 (76%)	0.45
LDH elevated		12 (17%)	14 (24%)	
# of nodal sites ≤ 4	135	17 (23%)	15 (25%)	0.99
# of nodal sites > 4		57 (77%)	46 (75%)	
# of nodal continuous	135	74 (100%)	61 (100%)	0.96
Stage I, II	137	8 (11%)	6 (10%)	1
Stage III, IV		67 (89%)	56 (90%)	

LDH, lactate dehydrogenase.